



Published in final edited form as:

*Cell Microbiol.* 2019 June ; 21(6): e13025. doi:10.1111/cmi.13025.

## Co-opting oxylipin signals in microbial disease

Mengyao Niu<sup>1</sup> and Nancy P. Keller<sup>1,2</sup>

<sup>1</sup>Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin

<sup>2</sup>Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin

### Abstract

Oxylipins, or oxygenated lipids, are universal signaling molecules across all kingdoms of life. These molecules, either produced by microbial pathogens or their mammalian host, regulate inflammation during microbial infection. In this review, we summarize current literature on the biosynthesis pathways of microbial oxylipins and their biological activity towards mammalian cells. Collectively, these studies have illustrated how microbial pathogens can modulate immune response and disease outcome via oxylipin-mediated mechanisms.

## 1 | INTRODUCTION

Microbes communicate with their hosts using small molecules, some unique to the microbe and some similar or even identical to host metabolites. Of the latter, oxygenated lipids called oxylipins are increasingly understood as key chemical signals that are produced and perceived by both microbe and host. These bioactive signaling molecules mediate many important biological processes, including immune homeostasis in plants and animals as well as microbial development. Despite that both microbial pathogen and the host can produce bioactive oxylipins, the role of microbial oxylipins in pathogenesis have been underappreciated. Herein we provide an overview of biosynthesis of oxylipins derived from prokaryotic and eukaryotic microorganisms that cause human infections, and the biological functions of microbial oxylipins in shaping the pathogenic relationships.

## 2 | MICROBIAL OXYLIPINS: ENZYMES AND PRODUCTS

Oxylipins are oxygenated derivatives of long chain mono- or poly-unsaturated fatty acids (PUFAs). Host oxylipins are mainly synthesized with 20:4 (n-6) arachidonic acid (AA), 20:5 (n-3) eicosapentaenoic acid (EPA), and 22:6(n-3) docosahexaenoic acid (DHA). Microbial pathogens can synthesize oxylipins using these PUFAs as well as other substrates such as 18:1 (n-9) oleic acid, 18:2 (n-6) linoleic acid (LA), and 18:3 (n-6) linolenic acid. Table 1 shows the enzymes and oxylipins produced by the pathogenic microbes discussed in this review. Microorganisms possess the same classes of eicosanoids biosynthesis enzymes as mammals including cyclooxygenases, lipoxygenases, and cytochrome P450s as well as

microbial specific enzymes (Figure 1). Other microbial proteins, such as phospholipases and epoxide hydrolases, don't directly catalyze oxylipin biosynthesis but alter PUFA substrate availability and modify host oxylipins during host-microbe encounters. Although some oxylipins can be non-enzymatically derived, this review will focus on microbial enzymatic sources of these lipids.

## 2.1 | Cyclooxygenase (COX)-like enzymes

Filamentous and dimorphic fungi contain upwards of four enzymes with significant homologies to mammalian cyclooxygenases COX-1 and COX-2 that synthesize prostaglandin H<sub>2</sub> (PGH<sub>2</sub>), the substrate for further enzymatic steps (Figure 1). The fungal COX-like oxygenases, termed Ppo proteins, have been best studied in *Aspergillus* spp. including the opportunistic pathogens *Aspergillus nidulans*, *Aspergillus flavus*, *Aspergillus fumigatus*, and *Aspergillus terreus* (Garscha et al., 2007; Hoffmann, Jernerén, & Oliw, 2013; Tsitsigiannis, Zarnowski, & Keller, 2004; Table 1). Ppo enzymes produce mono- or di-hydroxyl oxylipins derived from oleic acid and linoleic acid, and PpoA and PpoC also contribute to AA-derived prostaglandin formation (Kupfahl et al., 2012; Tsitsigiannis et al., 2005; Noverr, Toews, & Huffnagle, 2002). Ppo oxygenases contain a heme-containing oxygenase domain (similar to the vertebrate COX) and a cytochrome P450 domain, thus are also termed linoleate dioxygenase-cytochrome P450. One of these enzymes has also been biochemically characterized in the dimorphic valley fever causing fungus *Coccidioides immitis* (Oliw et al., 2016). Other fungal pathogens, including the thermal dimorphic fungus *Paracoccidioides brasiliensis* and pathogenic yeasts *Candida albicans*, *Candida parapsilosis* and *Cryptococcus neoformans*, can produce PGE<sub>2</sub> and other prostaglandins, yet the responsible COX has not been identified (Bordon et al., 2007; Erb-Downward and Noverr, 2007; Erb-Downward et al., 2008; Fischer and Keller, 2016).

The intestinal amebiasis-causing agent *Entamoeba histolytica* produces PGE<sub>2</sub> via a nuclear COX-like protein and this production is sensitive to the non-selective COX inhibitor aspirin (Dey et al., 2003). COX activity of the protease Gp63 in the Leishmania causing *Leishmania mexicana* was reported, using a chemiluminescence-based kit for COX activity (Estrada-Figueroa et al., 2018). Phylogenetic analysis revealed that the protozoan COX-like proteins, including Gp63 proteins from *L. mexicana* and the Chaga's disease agent *Trypanosoma cruzi* and the Cox-like protein of *E. histolytica*, are evolutionary distant from mammalian COXs (Estrada-Figueroa et al., 2018).

## 2.2 | Prostaglandin synthases and thromboxane synthase

In humans, the COX product PGH<sub>2</sub> serves as substrate for synthesizing various structurally similar oxylipins, including other prostaglandins PGD<sub>2</sub>, PGE<sub>2</sub> and PGF<sub>2α</sub>, prostacyclin PGI<sub>2</sub>, and thromboxane TXA<sub>2</sub> (Figure 1). Prostaglandin and thromboxane synthases were identified in microbial pathogens based on their biosynthetic property rather than homology to mammalian enzymes.

The African trypanosomiasis agent *Trypanosoma brucei*, the Leishmaniasis pathogen *Leishmania* spp., and malaria pathogen *Plasmodium falciparum* can produce PGD<sub>2</sub>, PGE<sub>2</sub>, and PGF<sub>2α</sub> when supplemented with AA (Araújo-Santos et al., 2014; Kubata et al., 1998;

Kubata et al., 2000; Kabututu et al., 2003). Unlike the *E. histolytica* COX activity, biosynthesis of these prostaglandins in *T. brucei* is not sensitive to COX inhibitors (Kubata et al., 2000). *Trypanosoma cruzi* produces TXA<sub>2</sub> as its major eicosanoid with minor amount of PGF<sub>2α</sub> (Ashton et al., 2007). PGF<sub>2α</sub> synthases were identified in *T. brucei* (TbPGFS), *T. cruzi* (TcOYE), and *Leishmania* spp. and reviewed in Kubata et al., (2007).

Several enzymes were found to contribute to prostaglandin production in pathogenic yeasts. *C. neoformans* laccase Lac1, a multicopper oxidoreductase, catalyzes conversion of PGG<sub>2</sub> to PGE<sub>2</sub> (Erb-Downward et al., 2008). In *C. albicans*, the oleate 9 fatty acid stearyl-coenzyme A desaturase Ole2 and the laccase homolog ferroxidase Fet3 contribute to PGE<sub>2</sub> production (Erb-Downward and Noverr, 2007). However, Ole2 of *C. parapsilosis* doesn't contribute to PGE<sub>2</sub> biosynthesis (Grózer et al., 2015). Three *C. parapsilosis* genes highly induced by AA were identified through RNA sequencing: CPAR2\_603600 (Fet3 homolog), CPAR2\_800020 (a putative thiolase) and CPAR2\_807710 (a putative Acyl-CoA dehydrogenase). The CPAR2\_603600 and CPAR2\_800020 proteins contribute to PGE<sub>2</sub> and PGD<sub>2</sub> production while the CPAR2\_807710 protein contributes to PGE<sub>2</sub> and 15-keto-PGE<sub>2</sub> production (Chakraborty et al., 2018).

### 2.3 | Lipoxygenases (LOXs)

*A. fumigatus* has two lipoxygenase homologs of human Alox15 and Alox5, denoted LoxA and LoxB (Heshof et al., 2014; Fischer et al., 2017). LoxB is secreted extracellularly and produces 13-hydroxyoctadecadienoic acid (13-HODE). A single Lox, the LoxB homolog is present in the carcinogenic fungus *Aspergillus flavus* (Horowitz Brown, 2008). Lipoxygenase activity with subsequent synthesis of leukotriene B<sub>4</sub> (LTB<sub>4</sub>) has been reported in *P. brasiliensis* although no associated enzyme has been characterized (Biondo et al., 2012).

Prokaryotic LOX-encoding genes are evolutionarily distant from human LOX and have been found predominantly in Gram-negative environmental species (Hansen et al., 2013). The first bacterial LOX to be identified was LoxA in the opportunistic bacterial pathogen *P. aeruginosa* (Vance et al., 2004). LoxA has multiple PUFA substrates and can convert AA and LA to 15S-hydroxyeicosatetraenoic acid (15-HETE) and 13-HODE. LoxA lacks the leukotriene synthase activity and whether it synthesizes lipoxin is still debatable (Banthiya et al., 2016; Deschamps et al., 2016; Vance et al., 2004). The Toxoplasmosis causing parasite *Toxoplasma gondii* produces the anti-inflammatory lipoxin LTA<sub>4</sub> and the extracted soluble tachyzoites antigen (STAg) converts AA to 15-HETE (Bannenberg et al., 2004).

Biosynthesis of specialized pro-resolving mediators, such as lipoxins and resolvins, often requires multiple enzymes, sometimes in different classes (Basil and Levy, 2016). A survey of *T. cruzi* oxylipins revealed production of AA derived prostaglandins and HETE, EPA derived RvE2, and DHA derived RvD1 and RvD5 from lysates of free trypomastigotes, suggesting presence of enzymes required for biosynthesis (Colas et al., 2018). RvE1 can be produced by *C. albicans* when supplemented with EPA, suggesting that cytochrome P450 and LOX activities are present (Hass-Stapleton et al., 2007).

## 2.4 | Other enzymes in oxylipin-mediated crosstalk: phospholipase and epoxide hydrolase

Human cytosolic phospholipase A<sub>2</sub> releases AA from plasma membrane to initiate inflammation (Dennis and Norris, 2015). Microbial phospholipases are widely present, and some can cleave host AA to mediate a host response. These studies are reviewed extensively in Ghannoum (2000) and Istivan and Coloe (2006). The most extensively characterized PLA is ExoU in *P. aeruginosa*. ExoU, a patatin-like phospholipase and cytotoxin, is injected through the Type III secretion system to the host cell (Anderson et al., 2011; Sato et al., 2003; Sawa et al., 2016). ExoU liberates AA from eukaryotic cell membrane, an activity required for its toxicity (Saliba et al., 2005; Rabin and Hauser, 2005). Other bacterial phospholipases implicated in host interaction include *Streptococcus pyogenes* phospholipase A<sub>2</sub> SlaA (Oda et al., 2017) and the ExoU homolog VipD in *Legionella pneumophila* (Gasper and Machner, 2014; Ku et al., 2012).

Epoxide hydrolase hydrolyzes epoxides to corresponding diols. *P. aeruginosa* secretes an epoxide hydrolase termed the CFTR inhibitory factor or Cif. Cif hydrolyzes 14,15-epoxyeicosatrienoic acid (14,15-EET) produced by epithelial cells to 14,15-dihydroxyeicosatrienoic acid (DHET; Flitter et al., 2016). Two epoxide hydrolases in *P. falciparum*, PfEH1 and PfEH2, hydrolyze epoxyeicosatrienoic acids (EETS) and epoxyoctadecenoic acids (EpOMEs) (Spillman et al., 2016). These microbial epoxide hydrolases have non-canonical active sites compared to human counterparts (Bahl et al., 2010; Spillman et al., 2016).

## 3 | MICROBIAL OXYLIPINS: EFFECT ON INFLAMMATION AND VIRULENCE

Pathology of microbial infections is dependent on the immunological state of the host as well as the metabolism, persistence, and growth of the pathogen. The host initiates and resolves infection through pro-inflammatory and anti-inflammatory responses mediated by AA, EPA, and DHA- derived lipid mediators and their cognate receptors (Basil and Levy, 2016; Dennis and Norris, 2015). Pro-inflammatory lipid mediators induce inflammatory cell infiltration and elevate production of chemokines and pro-inflammatory cytokines. Anti-inflammatory lipid mediators inhibit infiltration of inflammatory cells and induce anti-inflammatory cytokine production, which induces apoptosis of immune cells and resolves inflammation. Since many microbial pathogens can produce eicosanoids and other potentially immuno-modulatory oxylipins, they can significantly steer the immunological response and influence disease outcomes. Many studies – primarily with fungi - have illustrated that microbial oxylipins are also important for development and cell morphogenesis (Fischer and Keller, 2016; Deschamps et al., 2016). These effects may alter disease outcome; here we specifically focus on roles of microbial oxylipins as immune-modulators during host confrontation. Figure 2 depicts various interactions between microbial pathogens and host cells mediated by microbial oxylipins and associated enzymes.

### 3.1 | Fungal pathogens

Oxylipin mediated host crosstalk have been studied most predominantly in *Aspergillus*, *Candida*, and *Cryptococcus* spp., the three species that contribute to most of the fungal

attributed mortality (Brown, 2012). These fungi can produce the same oxylipins present in the host and those unique to the microbe.

It is currently not known if *Aspergillus* LA- derived oxylipins are synthesized *de novo* in animals but the *A. fumigatus* LoxB LA-metabolite 13-HODE is also made by humans and is implicated in airway hyper-responsiveness (Mabaliraian et al., 2013). *A. fumigatus* PpoC contributes to resisting phagocytosis and killing by murine bone marrow derived macrophages (Dagenais et al., 2008). An RNAi mutant with reduced expression of *ppoA*, *ppoB*, and *ppoC* shows lower prostaglandin production *in vitro* and increased virulence in a chemotherapeutic murine model of invasive aspergillosis (Tsitsigiannis et al., 2005). The mechanism of how AA and LA-derived oxylipins catalyzed by Ppo proteins mediate macrophage interaction and virulence remains to be elucidated.

Purified *C. albicans* and *C. neoformans* PGE<sub>2</sub> has an anti-inflammatory effect: it reduces chemokine IL-8 and inflammatory cytokine TNF- $\alpha$  production but increases anti-inflammatory IL-10 production in A549 epithelial cells (Noverr et al., 2001). Further study is required to assess whether the identified oxylipin producing enzymes in these pathogens (Table 1) mediate pathogenesis through altered PGE<sub>2</sub> production. Deletion mutants of the three *C. parapsilosis* enzymes mentioned earlier (CPAR2\_603600, CPAR2\_800020, and CPAR2\_807710) are more susceptible to phagocytosis and killing by human peripheral blood monocyte derived macrophages (PBMC-DM; Chakraborty et al., 2018). PBMC-DM infected by the *CPAR2\_807710* / strain produced higher levels of IL-6, TNF- $\alpha$  and IL-8. All three mutants showed reduced fungal burden in various organs in a murine model of intravenous infection (Chakraborty et al., 2018).

3-HETE produced by *C. albicans* can serve as substrate for human COX-2 to synthesize 3-OH-PGE<sub>2</sub> (Ciccoli et al., 2005). 3-OH-PGE<sub>2</sub> triggers increased IL-6 expression in A549 epithelial cells and cAMP release in Jurkat T cells, mediated by the PGE<sub>2</sub> cognate receptors EP3 and EP4, respectively. As *C. albicans* produces RvE1 that's structurally identical to human RvE1, synthetic RvE1 was used to study neutrophil phagocytosis and pathogenesis of *C. albicans*. Treatment of low concentrations of RvE1 enhances neutrophil phagocytosis and killing of *C. albicans* and intravenous injection of RvE1 reduces *C. albicans* replication in a murine model of intravenous *C. albicans* infection (Hass-Stapleton et al., 2007). However, it's unclear whether these findings are physiologically relevant and whether RvE1 itself inhibits *C. albicans* growth.

### 3.2 | Bacterial pathogens

While investigations on bacteria derived oxylipins are scarce, studies on *P. aeruginosa* enzymes, including the epoxide hydrolase Cif, the phospholipase ExoU, and the lipoxygenase LoxA, have shed light on mechanisms of oxylipin-mediated host crosstalk. These studies present a view that bacterial pathogens may have evolved to manipulate host immunity in environments where oxylipins and their substrates are abundant.

*Pseudomonas aeruginosa* colonizes immuno-compromised individuals, such as cystic fibrosis (CF) patients. Cif, a virulence factor in *P. aeruginosa* colonization of CF lungs, degrades the potent anti-inflammatory 14,15-EET from airway epithelial cells to less potent

14,15-DHET. This leads to reduced 15-epi LXA<sub>4</sub>, a pro-resolving product of neutrophils, and elevated inflammation (Bahl et al., 2011; Flitter et al., 2017). Furthermore, Cif activity in CF bronchial lavage fluid is positively associated with IL-8 level, and negatively associated with lung functions and 15-epi-LXA<sub>4</sub> abundance (Flitter et al., 2017). Cif also inhibits mucociliary beating and hinders mechanical clearance of *P. aeruginosa* during infection of reconstituted human bronchial epithelium and in a murine model of acute pneumonia (Hvorecny et al., 2018).

ExoU is a well-recognized virulence factor, cytotoxin, and phospholipase (Sawa et al., 2016). ExoU releases AA and increases PGE<sub>2</sub> and PGI<sub>2</sub> concentrations in culture supernatant of infected cells (Saliba et al., 2005; Plotkowski et al., 2008). ExoU expressing strains induce neutrophil production of LTB<sub>4</sub> and neutrophil trans-epithelial migration *in vitro*, and increase PGE<sub>2</sub> and LTB<sub>4</sub> production, innate immune cell infiltration, and myeloperoxidase activity during acute pulmonary infection in mice (Pazos et al., 2017; Saliba et al., 2005). A549 epithelial cells infected with ExoU-expressing *P. aeruginosa* have impaired antioxidant detoxification machinery and higher levels of oxidative metabolites, including lipid hydroperoxides, 8-isoprostanes, ROS, and NO (Da Cunha et al., 2015). The *L. pneumophila* homolog of ExoU, VipD disrupts endosomal membrane lipids and facilitates *L. pneumophila* escape from endosomal fusion in the Cos-1 cells (Gasper and Machner, 2014). *Streptococcus pyogenes* phospholipase A<sub>2</sub> SlaA increases monocyte adhesion to endothelial cells *in vitro* (Oda et al., 2017).

Recombinant *P. aeruginosa* LoxA modifies membrane phospholipids by forming 15-HETE and 13-HODE, which is associated with induction of red blood cell hemolysis (Banthiya et al., 2015). LoxA is highly expressed in *P. aeruginosa* isolated from CF lungs and is implicated in biofilm formation on biotic surfaces, such as epithelium (Deschamps et al., 2016; Starkey et al., 2009).

### 3.3 | Protozoan parasites

So far, all of the reported parasite derived oxylipins are present in mammals. As many of these organisms cannot grow in axenic culture, several studies have revealed parasite-host oxylipin signaling pathways by exploiting a mammalian receptor mutant. This tactic offers the additional value of insights into pharmacological control of parasite infections.

*Trypanosoma cruzi* produced TXA<sub>2</sub> and PGF<sub>2α</sub>, are important in maintaining long-term infection. TXB<sub>2</sub> derived from *T. cruzi*, the stable derivative of TXA<sub>2</sub>, consists most of the circulating TXB<sub>2</sub> in infected mice during later stage of infection (Ashton et al., 2007). Deletion of the TXA<sub>2</sub> receptor TP in mice results in increased inflammatory cell infiltration, increased parasitic load in myocardium, and increased host mortality (Ashton et al., 2007). These findings suggest that *T. cruzi* exploits the TXA<sub>2</sub>-TP signaling to prevent host from early death and maintain infection longevity. PGF<sub>2</sub> synthase TcOYE is important for completion and progression of its infective cycle (Díaz-Viraqué et al., 2018). The TcOYE overexpression mutant displays more aggressive parasitemia and increased parasitic load in cardiac tissue.

The *Leishmania* spp. protein Gp63 and its product PGF<sub>2α</sub> are implicated in mediating host responses to the parasite. Gp63 is a well-recognized virulence factor and was extensively reviewed prior to the knowledge that it possessed COX-like activity (Olivier et al., 2012). Comparison of *Leishmania amazonensis* gp63 RNAi mutants expressing differential levels of Gp63 revealed that Gp63 promotes parasite binding to J774 macrophages and intracellular survival (Chen et al., 2000). Future studies on Gp63 should consider its newly identified COX activity in interpreting past studies of such mutants. The PGF<sub>2α</sub> receptor FP of bone marrow derived macrophages localizes to the parasitophorous vacuoles when infected with *Leishmania infantum chagasi* (Araújo-Santos et al., 2014). Treatment with a FP inhibitor decreases the infection index of macrophage by various stages of *L. i. chagasi* (Araújo-Santos et al., 2014). Activation of PGF<sub>2α</sub>-FP signaling allows *L. i. chagasi* to evade the macrophage anti-parasitic activity. Therefore, blockade of this pathway may present a therapeutic avenue to manage parasitic load and treat Leishmaniasis.

Invasive infection of *E. histolytica* induces robust inflammation and tissue damage. *E. histolytica* or its secreted components induces IL-8 production by infected Caco-2 epithelial cells (Dey et al., 2008). This induction is absent using de-lipidized soluble components, aspirin treated *E. histolytica*, or Caco-2 cells with inhibited PGE<sub>2</sub> receptor EP4. The same group later found that the secreted components also decreases trans-epithelial resistance of the human colonic epithelial monolayer through dissociating the tight junction protein Claudin-4, which is abolished through aspirin pretreatment of *E. histolytica* or inhibition of EP4 (Lejeune et al., 2011). The role of the previously identified COX-like enzyme in these interactions is worth further investigation.

The aminopeptidase activity of PfeH2 and the epoxide hydrolase activity of PfeH1 and PfeH2 in *P. falciparum* were independently reported (Spillman et al., 2016; da Silva et al., 2016). The PfeH2 deletion mutant is more easily filtered outside of the infected erythrocytes, and the PfeH1 and PfeH2 overexpression mutants decreases abundance of several EETs and EpOMEs in infected erythrocytes.

## 4 | CONCLUSIONS

The critical nature of oxylipins in inflammation and infection is clear from myriad studies as reflected in the moniker ‘eicosanoid storm’ (Dennis and Norris, 2015). Yet the majority of these studies have focused solely on host oxylipins. Collectively, the studies in this review support an important but underappreciated role of microbial oxylipins in human infectious disease.

Where might the future directions microbial oxylipin research head? An increasing body of literature has reported that microbial extracellular vesicles modulate host immunological response (Joffe et al., 2016; Kuipers, et al., 2018). In mammalian systems, extracellular vesicles facilitate intercellular transport of eicosanoids and their biosynthetic machinery, mediating paracrine signaling (Boilard et al., 2018; Sagini et al., 2018). Proteins that mediate oxylipin biosynthesis and signaling, such as Cif from *P. aeruginosa* and the *Leishmania* COX Gp63 protein, are located in extracellular vesicles (Ghosh et al., 2013). Purified EVs from *C. albicans* and *C. neoformans* are internalized by macrophage and

dendritic cells and stimulate production of nitric oxide and proinflammatory cytokine (Oliveira et al., 2010; Vargas et al., 2015). Extracellular vesicles thus can serve as a site of oxylipin biosynthesis and a vehicle in shuffling the enzymes, substrates and products between the pathogen and the host. Additionally, roles for microbial oxylipins in microbial confrontations should also be explored more thoroughly in the context of the human microbiome (Fourie et al., 2017; Krause et al., 2015).

Finally, we note that one emerging theme from the research summarized in this review is that whereas some microbial oxylipins are identical to mammalian products and impact host processes, other microbial oxylipin products and/or their synthesizing enzymes are evolutionarily distant from those in mammals (Estrada-Figueroa et al., 2018; Hansen et al., 2013). Not only is it important to investigate the potential impacts of these structurally distinct microbial oxylipins on host immunological processes but the microbial chemical signatures may be useful for molecular diagnosis of the pathogen. Furthermore, biochemical studies on microbial specific enzymes could potentially pave a way to identifying new targets for future therapies.

## Acknowledgments

Funding information

National Institute of Health R01, Grant Number: AI065728–01

## REFERENCES

- Anderson DM, Schmalzer KM, Sato H, Casey M, Terhune SS, Haas AL, ... Frank DW (2011). Ubiquitin and ubiquitin-modified proteins activate the *Pseudomonas aeruginosa* T3SS cytotoxin, ExoU: Ubiquitin activation of ExoU. *Molecular Microbiology*, 82(6), 1454–1467. 10.1111/j.1365-2958.2011.07904.x [PubMed: 22040088]
- Araújo-Santos T, Rodríguez NE, Moura-Pontes S, Dixt UG, Abánades DR, Bozza PT, ... Borges VM (2014). Role of prostaglandin F2 $\alpha$  production in lipid bodies from *Leishmania infantum* chagasi: Insights on virulence. *The Journal of Infectious Diseases*, 210(12), 1951–1961. 10.1093/infdis/jiu299 [PubMed: 24850789]
- Ashton AW, Mukherjee S, Nagajyothi F, Huang H, Braunstein VL, Desruisseaux MS, ... Tanowitz HB (2007). Thromboxane A 2 is a key regulator of pathogenesis during *Trypanosoma cruzi* infection. *The Journal of Experimental Medicine*, 204(4), 929–940. 10.1084/jem.20062432 [PubMed: 17420269]
- Bahl CD, Morisseau C, Bomberger JM, Stanton BA, Hammock BD, O'Toole GA, & Madden DR (2010). Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. *Journal of Bacteriology*, 192(7), 1785–1795. 10.1128/JB.01348-09 [PubMed: 20118260]
- Bannenberg GL, Aliberti J, Hong S, Sher A, & Serhan C (2004). Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A 4 biosynthesis. *The Journal of Experimental Medicine*, 199(4), 515–523. 10.1084/jem.20031325 [PubMed: 14970178]
- Banthiya S, Kalms J, Galemou Yoga E, Ivanov I, Carpena X, Hamberg M, ... Scheerer P (2016). Structural and functional basis of phospholipid oxygenase activity of bacterial lipoxygenase from *Pseudomonas aeruginosa*. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, 1861(11), 1681–1692. 10.1016/j.bbalip.2016.08.002 [PubMed: 27500637]
- Banthiya S, Pekárová M, Kuhn H, & Heydeck D (2015). Secreted lipoxygenase from *Pseudomonas aeruginosa* exhibits biomembrane oxygenase activity and induces hemolysis in human red blood cells. *Archives of Biochemistry and Biophysics*, 584, 116–124. 10.1016/j.abb.2015.09.003 [PubMed: 26361973]



- Basil MC, & Levy BD (2016). Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. *Nature Reviews Immunology*, 16(1), 51–67. 10.1038/nri.2015.4
- Biondo GA, Dias-Melicio LA, Bordon-Graciani AP, Kurokawa CS, & Soares AMV (2012). Production of leukotriene B4 by *Paracoccidioides brasiliensis*: Eicosanoid production by *Paracoccidioides brasiliensis*. *Yeast*, 29(6), 201–208. 10.1002/yea.2900 [PubMed: 22628121]
- Boilard E (2018). Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA. *Journal of Lipid Research*, jlr – R084640.
- Bordon AP, Dias-Melicio LA, Acorci MJ, Biondo GA, Fecchio D, Peraçoli MTS, & de Soares ÂMVC (2007). Prostaglandin E2 production by high and low virulent strains of *Paracoccidioides brasiliensis*. *Mycopathologia*, 163(3), 129–135. 10.1007/s11046-007-0098-1 [PubMed: 17364218]
- Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, & White TC (2012). Hidden killers: Human fungal infections. *Science Translational Medicine*, 4(165), 165rv13–rv165rv13. 10.1126/scitranslmed.3004404
- Chakraborty T, Thuer E, Heijink M, Tóth R, Bodai L, Vágvölgyi C, ... Gácsér A (2018). Eicosanoid biosynthesis influences the virulence of *Candida parapsilosis*. *Virulence*, 9(1), 1019–1035. 10.1080/21505594.2018.1475797 [PubMed: 30052120]
- Chen D-Q, Kolli BK, Yadava N, Lu HG, Gilman-Sachs A, Peterson DA, & Chang K-P (2000). Episomal expression of specific sense and antisense mRNAs in *Leishmania amazonensis*: modulation of gp63 level in promastigotes and their infection of macrophages in vitro. *Infection and Immunity*, 68(1), 80–86. [PubMed: 10603371]
- Ciccoli R, Sahi S, Singh S, Prakash H, Zafiriou M-P, Ishdorj G, ... Nigam S (2005). Oxygenation by COX-2 (cyclo-oxygenase-2) of 3-HETE (3-hydroxyeicosatetraenoic acid), a fungal mimetic of arachidonic acid, produces a cascade of novel bioactive 3-hydroxyeicosanoids. *Biochemical Journal*, 390(3), 737–747. 10.1042/BJ20041995 [PubMed: 15869467]
- Colas R, Ashton A, Mukherjee S, Dalli J, Akide-Ndunge O, Huang H, ... Tanowitz H (2018). *Trypanosoma cruzi* produces the specialized pro-resolving mediators resolvin D1, resolvin D5, and resolvin E2. *Infection and Immunity*, 86 (4), e00688–17. doi: 10.1128/IAI.00688-17. [PubMed: 29358332]
- Da Cunha LG, Ferreira MF, de Moraes JA, Reis PA, Castro-Faria-Neto HC, Barja-Fidalgo C, ... Saliba AM (2015). ExoU-induced redox imbalance and oxidative stress in airway epithelial cells during *Pseudomonas aeruginosa* pneumosepsis. *Medical Microbiology and Immunology*, 204(6), 673–680. 10.1007/s00430-015-0418-x [PubMed: 25904542]
- Dagenais TRT, Chung D, Giles SS, Hull CM, Andes D, & Keller NP (2008). Defects in conidiophore development and conidium-macrophage interactions in a dioxxygenase mutant of *Aspergillus fumigatus*. *Infection and Immunity*, 76(7), 3214–3220. 10.1128/IAI.00009-08 [PubMed: 18443090]
- Da Silva FL, Dixon MWA, Stack CM, Teuscher F, Taran E, Jones MK, ... Skinner-Adams TS (2016). A *Plasmodium falciparum* S33 proline aminopeptidase is associated with changes in erythrocyte deformability. *Experimental Parasitology*, 169, 13–21. 10.1016/j.exppara.2016.06.013 [PubMed: 27373432]
- Dennis EA, & Norris PC (2015). Eicosanoid storm in infection and inflammation. *Nature Reviews Immunology*, 15(8), 511–523. 10.1038/nri3859
- Deschamps JD, Ogunsola AF, Jameson JB, Yasgar A, Flitter BA, Freedman CJ, ... Holman TR (2016). Biochemical and cellular characterization and inhibitor discovery of *Pseudomonas aeruginosa* 15-Lipoxygenase. *Biochemistry*, 55(23), 3329–3340. 10.1021/acs.biochem.6b00338 [PubMed: 27226387]
- Dey I, & Chadee K (2008). Prostaglandin E2 produced by *Entamoeba histolytica* binds to EP4 receptors and stimulates interleukin-8 production in human colonic cells. *Infection and Immunity*, 76(11), 5158–5163. 10.1128/IAI.00645-08 [PubMed: 18710858]
- Dey I, Keller K, Belley A, & Chadee K (2003). Identification and characterization of a cyclooxygenase-like enzyme from *Entamoeba histolytica*. *Proceedings of the National Academy of Sciences*, 100(23), 13561–13566.
- Díaz-Viraqué F, Chiribao ML, Trochine A, González-Herrera F, Castillo C, Liempi A, ... Robello C (2018). Old Yellow Enzyme from *Trypanosoma cruzi* exhibits in vivo prostaglandin F2 $\alpha$  synthase

- activity and has a key role in parasite infection and drug susceptibility. *Frontiers in Immunology*, 9 10.3389/fimmu.2018.00456
- Erb-Downward JR, Noggle RM, Williamson PR, & Huffnagle GB (2008). The role of laccase in prostaglandin production by *Cryptococcus neoformans*. *Molecular Microbiology*, 68(6), 1428–1437. 10.1111/j.1365-2958.2008.06245.x [PubMed: 18410494]
- Erb-Downward JR, & Noverr MC (2007). Characterization of prostaglandin E2 production by *Candida albicans*. *Infection and Immunity*, 75(7), 3498–3505. 10.1128/IAI.00232-07 [PubMed: 17470538]
- Estrada-Figueroa LA, Díaz-Gandarilla JA, Hernández-Ramírez VI, Arrieta-González MM, Osorio-Trujillo C, Rosales-Encina JL, ... Talamás-Rohana P (2018). *Leishmania mexicana* gp63 is the enzyme responsible for cyclooxygenase (COX) activity in this parasitic protozoa. *Biochimie*, 151, 73–84. 10.1016/j.biochi.2018.05.016 [PubMed: 29864507]
- Fischer GJ, Bacon W, Yang J, Palmer JM, Dagenais T, Hammock BD, & Keller NP (2017). Lipoxygenase activity accelerates programmed spore germination in *Aspergillus fumigatus*. *Frontiers in Microbiology*, 8 10.3389/fmicb.2017.00831
- Fischer GJ, & Keller NP (2016). Production of cross-kingdom oxylipins by pathogenic fungi: An update on their role in development and pathogenicity. *Journal of Microbiology*, 54(3), 254–264. 10.1007/s12275-016-5620-z
- Flitter BA, Hvorecny KL, Ono E, Eddens T, Yang J, Kwak DH, ... Bomberger JM (2017). *Pseudomonas aeruginosa* sabotages the generation of host proresolving lipid mediators. *Proceedings of the National Academy of Sciences*, 114(1), 136–141. 10.1073/pnas.1610242114
- Fourie R, Ells R, Kemp G, Sebolai OM, Albertyn J, & Pohl CH (2017). *Pseudomonas aeruginosa* produces aspirin insensitive eicosanoids and contributes to the eicosanoid profile of polymicrobial biofilms with *Candida albicans*. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, 117, 36–46. 10.1016/j.plefa.2017.01.008
- Garscha U, Jernerén F, Chung D, Keller NP, Hamberg M, & Oliw EH (2007). Identification of dioxygenases required for *Aspergillus* development: Studies of products, Stereochemistry, and the reaction mechanism. *Journal of Biological Chemistry*, 282(48), 34707–34718. 10.1074/jbc.M705366200 [PubMed: 17906293]
- Gaspar AH, & Machner MP (2014). VipD is a Rab5-activated phospholipase A1 that protects *Legionella pneumophila* from endosomal fusion. *Proceedings of the National Academy of Sciences*, 111(12), 4560–4565. 10.1073/pnas.1316376111
- Ghannoum MA (2000). Potential role of phospholipases in virulence and fungal pathogenesis. *Clinical Microbiology Reviews*, 13(1), 122–143. 10.1128/CMR.13.1.122-143 [PubMed: 10627494]
- Ghosh J, Bose M, Roy S, & Bhattacharyya SN (2013). *Leishmania donovani* targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. *Cell Host & Microbe*, 13(3), 277–288. 10.1016/j.chom.2013.02.005 [PubMed: 23498953]
- Grózer Z, Tóth A, Tóth R, Kecskeméti A, Vágvölgyi C, Nosanchuk JD, ... Gácsér A (2015). *Candida parapsilosis* produces prostaglandins from exogenous arachidonic acid and OLE2 is not required for their synthesis. *Virulence*, 6(1), 85–92. <https://doi.org/10.4161/1505594.2014.988097> [PubMed: 25654274]
- Haas-Stapleton EJ, Lu Y, Hong S, Arita M, Favoreto S, Nigam S, ... Agabian N (2007). *Candida albicans* modulates host defense by biosynthesizing the pro-resolving mediator resolvin E1. *PLoS ONE*, 2(12), e1316 10.1371/journal.pone.0001316 [PubMed: 18091990]
- Hansen J, Garreta A, Benincasa M, Fusté MC, Busquets M, & Manresa A (2013). Bacterial lipoxygenases, a new subfamily of enzymes? A phylogenetic approach. *Applied Microbiology and Biotechnology*, 97(11), 4737–4747. 10.1007/s00253-013-4887-9 [PubMed: 23624657]
- Heshof R, Jylhä S, Haarmann T, Jørgensen ALW, Dalsgaard TK, & de Graaff LH (2014). A novel class of fungal lipoxygenases. *Applied Microbiology and Biotechnology*, 98(3), 1261–1270. 10.1007/s00253-013-5392-x [PubMed: 24276623]
- Hoffmann I, Jernerén F, & Oliw EH (2013). Expression of fusion proteins of *Aspergillus terreus* reveals a novel allene oxide synthase. *Journal of Biological Chemistry*, 288(16), 11459–11469. 10.1074/jbc.M113.458257 [PubMed: 23479731]

- Horowitz Brown S, Zarnowski R, Sharpee WC, & Keller NP (2008). Morphological transitions governed by density dependence and lipoxygenase activity in *Aspergillus flavus*. *Applied and Environmental Microbiology*, 74(18), 5674–5685. 10.1128/AEM.00565-08 [PubMed: 18658287]
- Hvorecny KL, Dolben E, Moreau-Marquis S, Hampton TH, Shabaneh TB, Flitter BA, ... Madden DR (2018). An epoxide hydrolase secreted by *Pseudomonas aeruginosa* decreases mucociliary transport and hinders bacterial clearance from the lung. *American Journal of Physiology-Lung Cellular and Molecular Physiology*, 314(1), L150–L156. 10.1152/ajplung.00383.2017 [PubMed: 28982736]
- Istivan TS, & Coloe P (2006). Phospholipase A in Gram-negative bacteria and its role in pathogenesis. *Microbiology*, 152(5), 1263–1274. 10.1099/mic.0.28609-0 [PubMed: 16622044]
- Joffe LS, Nimrichter L, Rodrigues ML, & Del Poeta M (2016). Potential roles of fungal extracellular vesicles during infection. *mSphere*, 1(4). 10.1128/mSphere.00099-16
- Kabututu Z, Martin SK, Nozaki T, Kawazu S, Okada T, Munday CJ, ... Kubata BK (2003). Prostaglandin production from arachidonic acid and evidence for a 9,11-endoperoxide prostaglandin H2 reductase in *Leishmania*. *International Journal for Parasitology*, 33(2), 221–228. 10.1016/S0020-7519(02)00254-0 [PubMed: 12633659]
- Krause J, Geginat G, & Tammer I (2015). Prostaglandin E2 from *Candida albicans* stimulates the growth of *Staphylococcus aureus* in mixed biofilms. *PloS One*, 10(8), e0135404 10.1371/journal.pone.0135404 [PubMed: 26262843]
- Kubata BK, Duszenko M, Kabututu Z, Rawer M, Szallies A, Fujimori K, ... Hayaishi O (2000). Identification of a novel prostaglandin F2 $\alpha$  synthase in *Trypanosoma brucei*. *The Journal of Experimental Medicine*, 192(9), 1327–1338. 10.1084/jem.192.9.1327 [PubMed: 11067881]
- Kubata BK, Duszenko M, Martin KS, & Urade Y (2007). Molecular basis for prostaglandin production in hosts and parasites. *Trends in Parasitology*, 23(7), 325–331. 10.1016/j.pt.2007.05.005 [PubMed: 17531535]
- Kubata BK, Eguchi N, Urade Y, Yamashita K, Mitamura T, Tai K, ... Horii T (1998). *Plasmodium falciparum* produces prostaglandins that are pyrogenic, somnogenic, and immunosuppressive substances in humans. *The Journal of Experimental Medicine*, 188(6), 1197–1202. 10.1084/jem.188.6.1197 [PubMed: 9743538]
- Kubata BK, Kabututu Z, Nozaki T, Munday CJ, Fukuzumi S, Ohkubo K, ... Urade Y (2002). A key role for Old Yellow Enzyme in the metabolism of drugs by *Trypanosoma cruzi*. *The Journal of Experimental Medicine*, 196(9), 1241–1252. 10.1084/jem.20020885 [PubMed: 12417633]
- Ku B, Lee K-H, Park WS, Yang C-S, Ge J, Lee S-G, ... Oh B-H (2012). VipD of *Legionella pneumophila* targets activated Rab5 and Rab22 to interfere with endosomal trafficking in macrophages. *PLoS Pathogens*, 8(12), e1003082 10.1371/journal.ppat.1003082 [PubMed: 23271971]
- Kuipers ME, Hokke CH, Smits HH, & Nolte-'t Hoen ENM (2018). Pathogen-derived extracellular vesicle-associated molecules that affect the host immune system: An overview. *Frontiers in Microbiology*, 9 10.3389/fmicb.2018.02182
- Kupfahl C, Tsikas D, Niemann J, Geginat G, & Hof H (2012). Production of prostaglandins, isoprostanes and thromboxane by *Aspergillus fumigatus*: Identification by gas chromatography–tandem mass spectrometry and quantification by enzyme immunoassay. *Molecular Immunology*, 49(4), 621–627. 10.1016/j.molimm.2011.10.010 [PubMed: 22118804]
- Lejeune M, Moreau F, & Chadee K (2011). Prostaglandin E2 produced by *Entamoeba histolytica* signals via EP4 receptor and alters Claudin-4 to increase ion permeability of tight junctions. *The American Journal of Pathology*, 179(2), 807–818. 10.1016/j.ajpath.2011.05.001 [PubMed: 21683675]
- Mabalarajan U, Rehman R, Ahmad T, Kumar S, Singh S, Leishangthem GD, ... Ghosh B (2013). Linoleic acid metabolite drives severe asthma by causing airway epithelial injury. *Scientific Reports*, 3(1). 10.1038/srep01349
- Noverr MC, Toews GB, Huffnagle GB (2002). Production of prostaglandins and leukotrienes by pathogenic fungi. *Infection and Immunity*, 70(1), 400–402. 10.1128/IAI.70.1.400-402.2002 [PubMed: 11748207]

- Noverr MC, Phare SM, Toews GB, Coffey MJ, & Huffnagle GB (2001). Pathogenic yeasts *Cryptococcus neoformans* and *Candida albicans* produce immunomodulatory prostaglandins. *Infection and Immunity*, 69(5), 2957–2963. 10.1128/IAI.69.5.2957-2963.2001 [PubMed: 11292712]
- Oda M, Domon H, Kurosawa M, Isono T, Maekawa T, Yamaguchi M, ... Terao Y (2017). *Streptococcus pyogenes* phospholipase A2 induces the expression of adhesion molecules on human umbilical vein endothelial cells and aorta of mice. *Frontiers in Cellular and Infection Microbiology*, 7 10.3389/fcimb.2017.00300
- Olivier M, Atayde VD, Isnard A, Hassani K, & Shio MT (2012). *Leishmania* virulence factors: Focus on the metalloprotease GP63. *Microbes and Infection*, 14(15), 1377–1389. 10.1016/j.micinf.2012.05.014 [PubMed: 22683718]
- Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML, & Nimrichter L (2010). Extracellular vesicles from *Cryptococcus neoformans* modulate macrophage functions. *Infection and Immunity*, 78(4), 1601–1609. 10.1128/IAI.01171-09 [PubMed: 20145096]
- Oliw EH, Aragón M, Chen Y, & Jernerén F (2016). A new class of fatty acid allene oxide formed by the DOX-P450 fusion proteins of human and plant pathogenic fungi, *C. immitis* and *Z. tritici*. *Journal of Lipid Research*, 57(8), 1518–1528. 10.1194/jlr.M068981 [PubMed: 27282156]
- Pazos MA, Lanter BB, Yonker LM, Eaton AD, Pirzai W, Gronert K, ... Hurley BP (2017). *Pseudomonas aeruginosa* ExoU augments neutrophil transepithelial migration. *PLoS Pathogens*, 13(8), e1006548. [PubMed: 28771621]
- Plotkowski M-C, Brandão BA, de Assis M-C, Feliciano L-FP, Raymond B, Freitas C, ... Bozza PT (2008). Lipid body mobilization in the ExoU-induced release of inflammatory mediators by airway epithelial cells. *Microbial Pathogenesis*, 45(1), 30–37. 10.1016/j.micpath.2008.01.008 [PubMed: 18486438]
- Rabin SDP, & Hauser AR (2005). Functional regions of the *Pseudomonas aeruginosa* cytotoxin ExoU. *Infection and Immunity*, 73(1), 573–582. 10.1128/IAI.73.1.573-582.2005 [PubMed: 15618197]
- Sagini K, Costanzi E, Emiliani C, Buratta S, & Urbanelli L (2018). Extracellular vesicles as conveyors of membrane-derived bioactive lipids in immune system. *International Journal of Molecular Sciences*, 19(4), 1227 10.3390/ijms19041227
- Saliba AM, Nascimento DO, Silva MCA, Assis MC, Gayer CRM, Raymond B, ... Plotkowski MC (2005). Eicosanoid-mediated proinflammatory activity of *Pseudomonas aeruginosa* ExoU. *Cellular Microbiology*, 7(12), 1811–1822. 10.1111/j.1462-5822.2005.00635.x [PubMed: 16309466]
- Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, ... Long RM (2003). The mechanism of action of the *Pseudomonas aeruginosa*-encoded type III cytotoxin, ExoU. *The EMBO Journal*, 22(12), 2959–2969. [PubMed: 12805211]
- Sawa T, Hamaoka S, Kinoshita M, Kainuma A, Naito Y, Akiyama K, & Kato H (2016). *Pseudomonas aeruginosa* type III secretory toxin ExoU and its predicted homologs. *Toxins*, 8(11), 307 10.3390/toxins8110307
- Spillman NJ, Dalmia VK, & Goldberg DE (2016). Exported epoxide hydrolases modulate erythrocyte vasoactive lipids during *Plasmodium falciparum* infection. *mBio*, 7(5). 10.1128/mBio.01538-16
- Starkey M, Hickman JH, Ma L, Zhang N, De Long S, Hinz A, ... Parsek MR (2009). *Pseudomonas aeruginosa* rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. *Journal of Bacteriology*, 191(11), 3492–3503. 10.1128/JB.00119-09 [PubMed: 19329647]
- Tsitsigiannis DI, Zarnowski R, & Keller NP (2004). The lipid body protein, PpoA, coordinates sexual and asexual sporulation in *Aspergillus nidulans*. *Journal of Biological Chemistry*, 279(12), 11344–11353. 10.1074/jbc.M310840200 [PubMed: 14699095]
- Tsitsigiannis I, Bok J, Andes D, Nielson K, Frisvad J, Keller N (2005). *Aspergillus* cyclooxygenase-like enzymes are associated with prostaglandin production and virulence. *Infection and Immunity* 73 (8), 4548–4559. <https://doi:10.1128/IAI.73.8.4548-4559.2005> [PubMed: 16040966]
- Vance RE, Hong S, Gronert K, Serhan CN, & Mekalanos JJ (2004). The opportunistic pathogen *Pseudomonas aeruginosa* carries a secretable arachidonate 15-lipoxygenase. *Proceedings of the National Academy of Sciences*, 101(7), 2135–2139.


Vargas G, Rocha JDB, Oliveira DL, Albuquerque PC, Frases S, Santos SS, ... Nimrichter L (2015). Compositional and immunobiological analyses of extracellular vesicles released by *Candida albicans*: Extracellular vesicles from *Candida albicans*. *Cellular Microbiology*, 17(3), 389–407. 10.1111/cmi.12374 [PubMed: 25287304]

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript

**FIGURE 1.**

Eicosanoid biosynthesis pathways in animals. Arachidonic acid-derived eicosanoids are biosynthesized through cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) pathways. Cyclooxygenases, including COX-1 and COX-2, produce prostaglandin H<sub>2</sub> (PGH<sub>2</sub>) that is further converted by prostaglandin synthases (PGES, PGFS, PGDS), prostacyclin synthase (PGIS) and thromboxane synthase (TXAS) to prostaglandins, prostacyclin, and thromboxane respectively. Lipoxygenases, including Alox5, Alox15, Alox12, and Alox8 synthesize hydroperoxyeicosatetraenoic acids (HPETEs) that are further converted to various hydroxylated and epoxidized eicosanoids. Cytochrome P450 (CYP 450) enzymes catalyze formation of various epoxyeicosatrienoic acids (EETs), which are short-lived and rapidly converted to dihydroxyeicosatrienoic acid (DHETs). HETEs, hydroxyeicosatetraenoic acids; PGH<sub>2</sub>, prostaglandin H<sub>2</sub>; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; PGF<sub>2α</sub>, prostaglandin F<sub>2α</sub>; PGD<sub>2</sub>, prostaglandin D<sub>2</sub>; PGI<sub>2</sub>, prostacyclin; TXA<sub>2</sub>, thromboxane A<sub>2</sub>; PGES, PGE synthase; PGFS, PGF synthase; PGDS, PGD synthase; PGIS, PGI synthase; TXA, TXA synthase



**FIGURE 2.** Host-pathogen interactions mediated by microbial oxylipins and enzymes. (a) Eukaryotic microbial pathogens, predominantly pathogenic fungi and protozoan parasites, produce the same oxylipins as the host eicosanoids and those unique to microbes. Host cells in close contact with pathogens through either infection (endothelial cell and macrophage) or immune response (macrophage, neutrophil, epithelial cell) can recognize microbe-derived oxylipins and respond with altered functionality. (b) Bacterial pathogens, such as *Pseudomonas aeruginosa*, produce enzymes that influence the type and abundance of host-derived oxylipins, leading to skewed inflammatory state. These include the epoxide hydrolase Cif and the phospholipase A<sub>2</sub> ExoU. LoxA in *P. aeruginosa* also promotes biofilm formation on epithelial surface. IL-8, interleukin 8; IL-10, interleukin 10; TNF-α, tumor necrosis factor alpha; PGs, prostaglandins; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; PGD<sub>2</sub>, prostaglandin D<sub>2</sub>; PGF<sub>2α</sub>, prostaglandin F<sub>2α</sub>; 15-keto-PGE<sub>2</sub>, 15-keto-prostaglandin E<sub>2</sub>; RVE1, resolvin E1;

10R-HODE, 10R-hydroxyoctadecadienoic acid; TXA<sub>2</sub>, thromboxane A<sub>2</sub>; EP4, PGE receptor; FP, PGF receptor; TP, thromboxane receptor; TcOYE, *Trypanosoma cruzi* Old Yellow Enzyme; PpoC, Psi-producing oxygenase C; 14,15-EET, 14,15-epoxyeicosatrienoic acid; 14,15-DHET, 14,15-dihydroxyeicosatrienoic acid; 15-epi-LXA<sub>4</sub>, 15-epi-lipoxin A<sub>4</sub>; AA, arachidonic acid; LTB<sub>4</sub>, leukotriene B<sub>4</sub>; T3SS, Type III Secretion System; Cif, conductance regulator inhibitory factor

Author Manuscript

Author Manuscript






Author Manuscript






Author Manuscript



**TABLE 1**  
List of enzyme-derived microbial oxylipins associated with pathogenesis and their microbial origin

PUFA	Oxylipin name	Chemical structure	Producer species and biosynthetic enzymes	References
Arachidonic Acid	Prostaglandin D <sub>2</sub> (PGD <sub>2</sub> )		<i>C. albicans</i> C. <i>parapsilosis</i> (CPAR2_603600, CPAR2_800020, CPAR2_807710) <i>T. brucei</i> <i>P. falciparum</i>	Chakraborty et al., 2018; Kubata et al., 2000; Kubata et al., 1998; Noverr et al., 2001;
	Prostaglandin E <sub>2</sub> (PGE <sub>2</sub> )		<i>C. albicans</i> (Ole2, Fet3) <i>C. neoformans</i> (Lac1) <i>C. parapsilosis</i> (CPAR2_603600, CPAR2_800020) <i>P. brasiliensis</i> <i>A. fumigatus</i> (Ppo's) <i>E. histolytica</i> <i>T. cruzi</i> <i>T. brucei</i> <i>L. mexicana</i> <i>P. falciparum</i>	Chakraborty et al., 2018; Colas et al., 2018; Dey et al., 2003; Erb-Downward et al., 2008 Erb-Downward and Noverr, 2007; Estrada-Figueroa et al., 2018, Kubata et al., 2000; Kubata et al., 1998; Noverr et al., 2001; Tsitsigrannis et al., 2005
	Prostaglandin F <sub>2α</sub> (PGF <sub>2α</sub> )		<i>C. albicans</i> <i>C. neoformans</i> <i>T. cruzi</i> (TcOYE) <i>T. brucei</i> (TbPGFS) <i>L. major</i> , <i>L. donovani</i> , <i>L. tropica</i> <i>L. i. chagasi</i> <i>P. falciparum</i>	Araujo-Santos et al., 2014; Ashton et al., 2007; Colas et al., 2018; Kabutu et al., 2003; Kubata et al., 2000; Kubata et al., 1998; Noverr et al., 2001;
	Thromboxane A <sub>2</sub> (TXA <sub>2</sub> )		<i>C. albicans</i> <i>T. cruzi</i>	Ashton et al., 2007; Noverr et al., 2001

PUFA	Oxylipin name	Chemical structure	Producer species and biosynthetic enzymes	References
	15S-hydroxyicosatetraenoic acid (15-HETE)		<i>P. aeruginosa</i> (LoxA) <i>T. gondii</i> (STAg)	Bannenberg et al., 2004; Vance et al., 2004
	3S-hydroxy eicosatetraenoic acid (3S-HETE)		<i>C. albicans</i>	Ciccoli et al., 2005
	Leukotriene B <sub>4</sub> (LTB <sub>4</sub> )		<i>P. brasiliensis</i>	Bordon et al., 2007
	Lipoxin A <sub>4</sub> (LXA <sub>4</sub> )		<i>T. gondii</i>	Bannenberg et al., 2004
Linoleic Acid	13-hydroxyoctadecadienoic acid (13-HODE)		<i>P. aeruginosa</i> (LoxA) <i>A. fumigatus</i> (LoxB)	Banthiya et al., 2015; Fischer et al., 2017;


PUFA	Oxylipin name	Chemical structure	Producer species and biosynthetic enzymes	References
	10R-hydroxyoctadecadienoic acid (10R-HODE)		<i>A. fumigatus</i> (PpoC) <i>A. nidulans</i> (PpoC) <i>A. terreus</i> (ATEG_03992)	Garscha et al., 2007; Hoffmann et al., 2013
	8R-hydroxyoctadecadienoic acid (8R-HODE)		<i>A. nidulans</i> (PpoA) <i>A. fumigatus</i> (PpoA) <i>C. immitis</i> (8R-DOX-AOS)	Garscha et al., 2007; Oliw et al., 2016; Tsitsigiannis, Zarnowski, & Keller, 2004
	5S,8R-dihydroxyoctadecadienoic acid (5S,8R-diHODE)		<i>A. fumigatus</i> (PpoA)	Garscha et al., 2007
Eicosapentaenoic Acid	Resolvin E1 (RvE1)		<i>T. cruzi</i> <i>C. albicans</i>	Colas et al., 2018; Hass-Stapleton et al., 2007
	Resolvin E2 (RvE2)		<i>T. cruzi</i>	Colas et al., 2018

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

PUFA	Oxylipin name	Chemical structure	Producer species and biosynthetic enzymes	References
Docosahexaenoic Acid	Resolvin D1 (RvD1)		<i>T. cruzi</i>	Colas et al., 2018